1. Home
  2. NDRA vs BIAF Comparison

NDRA vs BIAF Comparison

Compare NDRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

HOLD

Current Price

$5.44

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$9.69

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDRA
BIAF
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
9.2M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
NDRA
BIAF
Price
$5.44
$9.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
54.4K
6.7M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
84.32
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$2.96
$0.33
52 Week High
$9.83
$20.35

Technical Indicators

Market Signals
Indicator
NDRA
BIAF
Relative Strength Index (RSI) 49.23 61.03
Support Level $4.43 $1.52
Resistance Level $6.35 $20.35
Average True Range (ATR) 0.63 2.63
MACD -0.06 -0.19
Stochastic Oscillator 23.71 36.99

Price Performance

Historical Comparison
NDRA
BIAF

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: